Toxicology, Including Therapeutic Drug Monitoring
Sandra Fuentes Cantero,Sebastián Eustaquio Martín Pérez,I Rodríguez Martín,Antonio Pérez,V. Sánchez Margalet,Antonio León Justel,Travis Hee Wai,Chao Wang,Bo Lin,Min Lin,Zhi Lin,Anna Abratis,Frank Streit,Moritz Schnelle,Manuel Wallbach,Nils Kunze-Szikszay,S Schnitzler,Julie Schanz,Lutz Binder,Ivana Marković
DOI: https://doi.org/10.1515/cclm-2021-5037
2021-01-01
Abstract:BACKGROUND-AIMPharmacogenetics is a discipline oriented to the study of the genetic basis of interindividual differences in the response to drugs, both at the level of efficacy and safety.One of the most widely used applications of Pharmacogenetics in clinical practice is the genetic test for HLA-B*5701 in patients who are going to start treatment with abacavir, due to its relationship with the hypersensitivity reaction it produces.Other adverse reactions of this type are: Relationship HLA-B15.02 with Steven-Johnson Syndrome and toxic epidermal necrolysis by carbamazepine, relationship HLA-B58.01 with Hypersensitivity Syndrome, Steven Johnson Syndrome and toxic epidermal necrolysis by allopurinol, relationship HLA-B35 with skin eruption by nevirapine and relationship HLA-B13.01 with hypersensitivity reaction induced by dapsone (DIHR).The objective of the study is to determine the prevalence of the HLA-B57.01 allele and the HLA-B35.05,HLA-B58.01,HLA-B15.02 and HLA-B13.01 alleles associated with adverse drug reactions in our healthcare area. METHODSDescriptive observational study of patients with HIV diagnosis, with request for genotyping HLA-B57.01 in our hospital area between July 2016 and September 2019 They were a total of 613 patients.Maxwell® 16 System, Blood DNA Purification System, was used to isolate the DNA in an automated way, which was later amplified by PCR.A strip probe assay, INNO-LiPAHLA-B Update Plus, was then used to determine the molecular typing of human leukocyte antigen (HLA) B alleles.The results were analyzed using Excel. RESULTSTo determine the prevalence of HLA-B alleles, an Excel database was created with a total of 613 samples.A prevalence of 3.75% was found for the HLA B57.01 allele.The prevalences of the other alleles with their respective confidence intervals (IC95%) and number of patients are detailed below: HLA-B 57.01 3,75% (2,51-5,57) 23 patients, HLA-B 58 0,82% (0,35-1,89) 5 patients, HLA-B35 9,79% (7,68-12,40) 60 patients, HLA-B15 1,14% (0,55-2,34) 7 patients and HLA-B13 1,63% (0,89-2,98) 10 patients. CONCLUSIONSThe calculated prevalences are lower than those described by other studies, such as the PREDICT-1 study with the participation of 15 European countries.We also found a high prevalence of the HLA-B35 allele, associated with adverse reactions to Nevirapine, more particularly the skin eruption induced by this second line antiretroviral in Spain.This high prevalence of HLA-B alleles associated with drug intolerance in our HIV population suggests that the determination of these alleles may be of great importance and utility in routine clinical practice in the at-risk population.